Breaking News, Collaborations & Alliances, Trials & Filings

Biocon and Mylan Receive ANVISA Approval

For the first biosimilar Trastuzumab to be approved in Brazil

Biosimilar Trastuzumab, co-developed by Biocon and Mylan, has been approved by ANVISA, the Brazilian regulatory agency, through their partner Libbs Farmaceutica (Libbs), a leading Brazilian pharmaceutical company.   This is the first biosimilar Trastuzumab to be approved in Brazil and is indicated for the treatment of overexpressing HER2-positive metastatic breast cancer, HER2-positive early stage breast cancer and HER2-positive advanced gastric cancer. Libbs will commercialize the produ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters